X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare JUBILANT LIFE SCIENCES with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs IPCA LABS - Comparison Results

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES IPCA LABS JUBILANT LIFE SCIENCES/
IPCA LABS
 
P/E (TTM) x 16.5 29.2 56.5% View Chart
P/BV x 4.3 3.5 125.4% View Chart
Dividend Yield % 0.4 0.1 309.0%  

Financials

 JUBILANT LIFE SCIENCES   IPCA LABS
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-14
IPCA LABS
Mar-18
JUBILANT LIFE SCIENCES/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs187695 26.9%   
Low Rs65400 16.3%   
Sales per share (Unadj.) Rs364.3260.2 140.0%  
Earnings per share (Unadj.) Rs6.819.0 36.1%  
Cash flow per share (Unadj.) Rs24.533.1 74.1%  
Dividends per share (Unadj.) Rs3.001.00 300.0%  
Dividend yield (eoy) %2.40.2 1,304.6%  
Book value per share (Unadj.) Rs164.9213.0 77.4%  
Shares outstanding (eoy) m159.28126.20 126.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.32.1 16.4%   
Avg P/E ratio x18.428.9 63.7%  
P/CF ratio (eoy) x5.116.6 31.0%  
Price / Book Value ratio x0.82.6 29.7%  
Dividend payout %43.85.3 831.4%   
Avg Mkt Cap Rs m20,06169,120 29.0%   
No. of employees `0006.213.3 46.7%   
Total wages/salary Rs m11,0527,359 150.2%   
Avg. sales/employee Rs Th9,383.02,477.4 378.7%   
Avg. wages/employee Rs Th1,786.9555.2 321.8%   
Avg. net profit/employee Rs Th176.3180.6 97.6%   
INCOME DATA
Net Sales Rs m58,03432,836 176.7%  
Other income Rs m191418 45.6%   
Total revenues Rs m58,22433,254 175.1%   
Gross profit Rs m5,7864,505 128.4%  
Depreciation Rs m2,8121,777 158.2%   
Interest Rs m3,237240 1,347.7%   
Profit before tax Rs m-722,905 -2.5%   
Minority Interest Rs m-2860-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m2,1450-   
Tax Rs m696511 136.3%   
Profit after tax Rs m1,0902,394 45.5%  
Gross profit margin %10.013.7 72.7%  
Effective tax rate %-965.917.6 -5,490.5%   
Net profit margin %1.97.3 25.8%  
BALANCE SHEET DATA
Current assets Rs m29,28019,455 150.5%   
Current liabilities Rs m38,91210,076 386.2%   
Net working cap to sales %-16.628.6 -58.1%  
Current ratio x0.81.9 39.0%  
Inventory Days Days8498 86.2%  
Debtors Days Days5167 75.7%  
Net fixed assets Rs m55,71220,260 275.0%   
Share capital Rs m155252 61.2%   
"Free" reserves Rs m20,96826,633 78.7%   
Net worth Rs m26,26526,886 97.7%   
Long term debt Rs m17,1692,340 733.7%   
Total assets Rs m88,60641,173 215.2%  
Interest coverage x1.013.1 7.5%   
Debt to equity ratio x0.70.1 751.0%  
Sales to assets ratio x0.70.8 82.1%   
Return on assets %4.96.4 76.3%  
Return on equity %4.28.9 46.6%  
Return on capital %11.610.8 107.5%  
Exports to sales %37.847.6 79.3%   
Imports to sales %16.514.9 110.8%   
Exports (fob) Rs m21,93315,642 140.2%   
Imports (cif) Rs m9,5674,884 195.9%   
Fx inflow Rs m22,00415,642 140.7%   
Fx outflow Rs m11,7494,884 240.6%   
Net fx Rs m10,25510,759 95.3%   
CASH FLOW
From Operations Rs m8,0263,411 235.3%  
From Investments Rs m-1,744-1,354 128.8%  
From Financial Activity Rs m-4,447-1,304 341.0%  
Net Cashflow Rs m1,834753 243.6%  

Share Holding

Indian Promoters % 45.6 45.9 99.3%  
Foreign collaborators % 3.5 0.0 -  
Indian inst/Mut Fund % 8.7 11.4 76.3%  
FIIs % 21.2 25.3 83.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 17.4 121.3%  
Shareholders   23,815 36,892 64.6%  
Pledged promoter(s) holding % 15.9 2.1 740.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   WYETH LTD  PFIZER  ALKEM LABORATORIES  SUN PHARMA  PIRAMAL ENTERPRISES  

Compare JUBILANT LIFE SCIENCES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 207 Points Higher; Healthcare Stocks Witness Buying(Closing)

Indian share markets continued to trade in the green during the closing hours of the trading session and ended the day on a positive note.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY19); Net Profit Up 39.4% (Quarterly Result Update)

Jul 31, 2018 | Updated on Jul 31, 2018

For the quarter ended June 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 39.4% YoY). Sales on the other hand came in at Rs 21 bn (up 30.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY18); Net Profit Up 1.4% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 1.4% YoY). Sales on the other hand came in at Rs 23 bn (up 37.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY18); Net Profit Up 15.6% (Quarterly Result Update)

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, IPCA LABS has posted a net profit of Rs 513 m (up 15.6% YoY). Sales on the other hand came in at Rs 8 bn (up 17.6% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Is Franklin India Smaller Companies Fund Worth Your Money(Outside View)

Aug 2, 2018

Although positioned as a small cap fund, Franklin India Smaller Companies Fund has been investing a significant portion of its assets in mid-caps along with a nominal exposure to large caps.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Aug 14, 2018 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES 8-QTR ANALYSIS

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS